Publications by authors named "E J Diver"
Background: Adolescent and young adult (AYA) females are vulnerable to psychological sequelae following cancer diagnosis and treatment. Fear of cancer recurrence (FCR) is well-documented in cancer survivors, however AYA survivors of breast and gynaecological cancers are less well-studied. Moreover, little is known about scan-related fears and anxiety ('scanxiety') in survivors of any age group.
View Article and Find Full Text PDFBackground: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a phase II, global, open-label, single-arm trial of MIRV as third-line or greater (≥3L) treatment in patients with FRα-positive (≥75% of cells with ≥2+ staining intensity) recurrent platinum-sensitive ovarian cancer (PSOC).
Patients And Methods: Participants received MIRV (6 mg/kg adjusted ideal body weight every 3 weeks) until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
Article Synopsis
- Platinum-sensitive ovarian cancer (PSOC) is commonly treated with platinum-based chemotherapy plus bevacizumab, but patients often face disease progression within a year, indicating a need for new treatment strategies.
- Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate targeting folate receptor alpha, has shown promising results when used with bevacizumab, particularly in patients with high levels of FRα.
- The ongoing Phase III GLORIOSA trial aims to compare the effectiveness of MIRV plus bevacizumab against bevacizumab alone for patients with FRα-high PSOC after responding to previous treatment.
Purpose: To report the results of OPAL (ClinicalTrials.gov identifier: NCT03574779) cohort A, a single-arm substudy of niraparib plus dostarlimab and bevacizumab for the treatment of advanced, platinum-resistant ovarian cancer (PROC).
Methods: Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib (200 or 300 mg once daily), dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), and bevacizumab (15 mg/kg once every 3 weeks).
Favorable Outcome of High-grade Endometrial Stromal Sarcoma in an Adolescent.
J Pediatr Hematol Oncol
July 2024
Article Synopsis
- High-grade endometrial stromal sarcoma is a rare, aggressive tumor that typically affects older women and has a poor survival rate of 30-40%.
- A 16-year-old patient with this condition, who had metastases in her lymph nodes and lungs, achieved long-term survival following complete tumor removal, chemotherapy, and radiation.
- The case also revealed a new type of genetic translocation, suggesting that aggressive treatment and fertility preservation are vital for young patients diagnosed with this cancer.